Le Lézard
Classified in: Health
Subject: CCA

Varian to Discuss New Reporting Standards


PALO ALTO, Calif., Jan. 3, 2018 /PRNewswire/ -- Varian (NYSE: VAR) today announced that it will webcast a conference call to discuss its transition to the new Accounting Standard Codification 606. No financial information concerning the just completed first quarter of fiscal year 2018 will be discussed. The webcast will start at 1:30 p.m. PT on Thursday, January 11, 2018. The live webcast will be available on the Varian Investor Relations website at www.varian.com/investors.

About Varian
Varian focuses energy on saving lives and is the world's leading manufacturer of medical devices and software for treating and managing cancer. Headquartered in Palo Alto, California, Varian employs approximately 6,500 people around the world. For more information, visit http://www.varian.com and follow @VarianMedSys on Twitter.

Investor Relations Contact

J. Michael Bruff
Vice President, Investor Relations
+1 (650) 424-5163
[email protected]

Press Contact

Mark Plungy
Director, Public Relations
+1 (650) 424-5630
[email protected]

Varian Medical Systems Logo

 

SOURCE Varian


These press releases may also interest you

at 04:00
Bioforum the Data Masters Introduces SUBMIT24: A Free of Charge and Revolutionary CDISC CORE-Based Clinical Data Validation Tool
Bioforum, the Data Masters, a leading contract research organization (CRO) focused on the delivery of biometric services and solutions to the global clinical trials industry, today announced the launch of SUBMIT24 in its beta version during Q3 2024,...

at 04:00
TVM Capital Healthcare Announces US$ 17 Million Investment into neurocare
TVM Capital Healthcare, a specialist healthcare private equity firm headquartered in Dubai and...

at 03:26
Calliditas Announces Positive NefIgArd Open Label Extension Results
Calliditas Therapeutics AB , ("Calliditas") today announced that the global open-label extension (OLE) study to the Phase 3 NefIgArd study showed a treatment response consistent with the NefIgArd study across endpoints of urine protein to creatinine...

at 03:00
Precision oncology company Flindr Therapeutics announces ?20 million Series A financing to advance first-in-class small molecule inhibitors
Flindr...

at 03:00
CSL Vifor and Travere Therapeutics Announce European Commission approves FILSPARI® (sparsentan) for the treatment of IgA Nephropathy
CSL Vifor and Travere Therapeutics, Inc., today announced that the European Commission has granted conditional marketing authorization (CMA) for FILSPARI (sparsentan) for the...

at 03:00
Tetra Pharm Technologies and Glysious Announce Collaboration to Develop Transdermal Combination Drugs Targeting the Endocannabinoid System
Tetra Pharm Technologies and Glysious are pleased to announce a strategic collaboration aimed at developing a ground-breaking transdermal drug delivery system complementing several of Tetra Pharm Technologies' pipeline candidates. The...

More news about Health...


News published on and distributed by: